A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia.
The goals of this study are to learn:
Inclusion Criteria:
Exclusion Criteria:
Atlantis, Florida 33462, United States
Fort Myers, Florida 33912, United States
Mar del Plata, Buenos Aires B7600FZN, Argentina
Buenos Aires, Buenos Aires F.D. C1427CCP, Argentina
Milan, Lombardy 20122, Italy
Roma, 00168, Italy
Kawasaki, Kanagawa 210-0852, Japan
tabashi City, Tokyo 173-0015, Japan
's-Hertogenbosch, North Brabant 5223 LA, Netherlands
Aberdeen, Aberdeen City AB25 2XE, United Kingdom